Melissa A. Laudano, MD, highlights 3 studies in overactive bladder/incontinence being presented at the 2023 American Urological Association Annual Meeting.
In this video, Melissa A. Laudano, MD, discusses 3 studies in overactive bladder/incontinence being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Laudano is an assistant professor of urology at Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York.
The following abstracts were previewed:
1. LBA01-05 (Heesakkers et al):Pivotal study of a novel wirelessly powered, patient tailored programmed, tibial neurostimulator for the treatment of patients with overactive bladder
2. LBA01-18 (Wada et al): Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter, prospective randomized crossover trial
3. LBA01-19 (Peters et al): Long-term efficacy and safety of URO-902 (PVAX/HSLO) in women with overactive bladder and urge urinary incontinence: final results of a phase 2a trial
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.